Trial Profile
A study to evaluate the circulating miRNAs levels after fingolimod treatment in patients with relapsing remitting multiple sclerosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 20 Dec 2015 New trial record